# NHS Cancer Jab Cuts Treatment Time Dramatically
The NHS will roll out a new injectable immunotherapy drug that slashes administration time from hours to minutes. Patients currently spend substantial time in hospital receiving intravenous infusions of existing cancer treatments. This new formulation eliminates that burden.
The injectable version delivers the same immunotherapy dose subcutaneously, similar to a standard vaccination. Treatment sessions that once consumed entire afternoons now take under five minutes. Thousands of cancer patients will gain access to this faster option.
The time savings matter practically. Patients avoid lengthy hospital visits. Healthcare workers deploy resources more efficiently. Hospital capacity pressures ease when procedures shrink from hours to minutes.
Immunotherapy drugs train the immune system to attack cancer cells. This injectable maintains the same therapeutic effect as intravenous versions while removing logistical friction from treatment. Faster administration doesn't compromise efficacy.
The NHS decision reflects evidence supporting the injectable formulation's performance. Clinical data demonstrated equivalent outcomes between injection and infusion methods. This breakthrough removes a genuine burden from cancer patients already managing intensive treatment schedules.